Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 45Breast Neoplasms 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Lymphoma, Large B-Cell, Diffuse 41Lymphoma, Non-Hodgkin 39Multiple Myeloma 35Leukemia 34Melanoma 32Leukemia, Lymphocytic, Chronic, B-Cell 32Recurrence 31Leukemia, Myeloid, Acute 28Lymphoma, Follicular 27Lymphoma, B-Cell 25Ovarian Neoplasms 24Lymphoma, Mantle-Cell 23Neoplasm Metastasis 22Hematologic Neoplasms 19Pancreatic Neoplasms 18Myelodysplastic Syndromes 18Hodgkin Disease 18Burkitt Lymphoma 16Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Triple Negative Breast Neoplasms 12Lymphoma, B-Cell, Marginal Zone 12Colorectal Neoplasms 12Stomach Neoplasms 11Waldenstrom Macroglobulinemia 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Carcinoma, Hepatocellular 9

Interventions

fludarabine 1Cyclophosphamide 14-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Philadelphia Chromosome × Cyclophosphamide × Clear all
NCT05442515 2026-05-28

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
130 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Philadelphia Chromosome, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡